{"entity":{"id":"nct07689201","kind":"trial","name":"A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib","aka":[],"tldr":"A phase 2 trial of Velzatinib in advanced solid tumours, run by GlaxoSmithKline, now recruiting.","summary":"A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib is a phase 2 interventional study registered as NCT07689201 by GlaxoSmithKline, with 24 participants planned, started 2026-08-17 and due to reach its primary completion in 2027-11-29. Interventions recorded: Velzatinib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07689201","url":"https://clinicaltrials.gov/study/NCT07689201"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["velzatinib"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07689201","phase":"2","setting":"A Phase 2, Single-arm, Multicenter, Open-Label Study of Velzatinib (GSK6042981) in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib, Sunitinib, Regorafenib, and Pimitespib Therapies (StrateGIST J)","sponsor":"GlaxoSmithKline","enrolled":24,"outcomes":[]},"route":"/trials/nct07689201/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"velzatinib","kind":"drug","name":"Velzatinib","route":"/drugs/velzatinib/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}